This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rybak, M. J.
Right arrow Articles by Kaatz, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rybak, M. J.
Right arrow Articles by Kaatz, G. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 1998, p. 721-724, Vol. 42, No. 3
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Comparative In Vitro Activities and Postantibiotic Effects of the Oxazolidinone Compounds Eperezolid (PNU-100592) and Linezolid (PNU-100766) versus Vancomycin against Staphylococcus aureus, Coagulase-Negative Staphylococci, Enterococcus faecalis, and Enterococcus faecium

Michael J. Rybak,1,2,3,* Diane M. Cappelletty,1,2,3 Tabitha Moldovan,1,2 Jeffrey R. Aeschlimann,1,2 and Glenn W. Kaatz1,2,3

The Anti-Infective Research Laboratory, Department of Pharmacy Services, Detroit Receiving Hospital/University Health Center,1 College of Pharmacy and Allied Health Professions,2 and Department of Internal Medicine, Division of Infectious Diseases, School of Medicine,3 Wayne State University, Detroit, Michigan 48201

Received 7 July 1997/Returned for modification 21 November 1997/Accepted 22 December 1997

The activities of the oxazolidinone antibacterial agents eperezolid (PNU-100592) and linezolid (PNU-100766) were compared with that of vancomycin against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus (n = 200), coagulase-negative staphylococci (n = 100), and vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium (n = 50). Eperezolid and linezolid demonstrated good in vitro inhibitory activity, regardless of methicillin susceptibility for staphylococci (MIC at which 90% of the isolates are inhibited [MIC90] range, 1 to 4 µg/ml) or vancomycin susceptibility for enterococci (MIC90 range, 1 to 4 µg/ml). In time-kill studies, eperezolid and linezolid were bacteriostatic in action. A postantibiotic effect of 0.8 ± 0.5 h was demonstrated for both eperezolid and linezolid against S. aureus, S. epidermidis, E. faecalis, and E. faecium.

* Corresponding author. Mailing address: The Anti-Infective Research Laboratory, Department of Pharmacy Services (1B), Detroit Receiving Hospital/University Health Center, 4201 St. Antoine Blvd., Detroit, MI 48201. Phone: (313) 745-4554. Fax: (313) 993-2522. E-mail: mrybak{at}dmc.org.

Antimicrobial Agents and Chemotherapy, March 1998, p. 721-724, Vol. 42, No. 3
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Laue, H., Valensise, T., Seguin, A., Lociuro, S., Islam, K., Hawser, S. (2009). In Vitro Bactericidal Activity of Iclaprim in Human Plasma. Antimicrob. Agents Chemother. 53: 4542-4544 [Abstract] [Full Text]  
  • Clark, C., Ednie, L. M., Lin, G., Smith, K., Kosowska-Shick, K., McGhee, P., Dewasse, B., Beachel, L., Caspers, P., Gaucher, B., Mert, G., Shapiro, S., Appelbaum, P. C. (2009). Antistaphylococcal Activity of Dihydrophthalazine Antifolates, a Family of Novel Antibacterial Drugs. Antimicrob. Agents Chemother. 53: 1353-1361 [Abstract] [Full Text]  
  • Baldoni, D., Haschke, M., Rajacic, Z., Zimmerli, W., Trampuz, A. (2009). Linezolid Alone or Combined with Rifampin against Methicillin-Resistant Staphylococcus aureus in Experimental Foreign-Body Infection. Antimicrob. Agents Chemother. 53: 1142-1148 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Skhirtladze, K., Hutschala, D., Fleck, T., Thalhammer, F., Ehrlich, M., Vukovich, T., Muller, M., Tschernko, E. M. (2006). Impaired Target Site Penetration of Vancomycin in Diabetic Patients following Cardiac Surgery.. Antimicrob. Agents Chemother. 50: 1372-1375 [Abstract] [Full Text]  
  • Jacqueline, C., Navas, D., Batard, E., Miegeville, A.-F., Le Mabecque, V., Kergueris, M.-F., Bugnon, D., Potel, G., Caillon, J. (2005). In Vitro and In Vivo Synergistic Activities of Linezolid Combined with Subinhibitory Concentrations of Imipenem against Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 45-51 [Abstract] [Full Text]  
  • Mogenet, I., Raetz-Dillon, S., Canonge, J.-M., Archambaud, M., Bonnet, E. (2004). Successful Treatment of Staphylococcus epidermidis Hip Prosthesis Infection with Oral Linezolid. The Annals of Pharmacotherapy 38: 986-988 [Abstract] [Full Text]  
  • Brown, J., Freeman, B. B III (2004). Combining Quinupristin/Dalfopristin with Other Agents for Resistant Infections. The Annals of Pharmacotherapy 38: 677-685 [Abstract] [Full Text]  
  • Bernardo, K., Pakulat, N., Fleer, S., Schnaith, A., Utermohlen, O., Krut, O., Muller, S., Kronke, M. (2004). Subinhibitory Concentrations of Linezolid Reduce Staphylococcus aureus Virulence Factor Expression. Antimicrob. Agents Chemother. 48: 546-555 [Abstract] [Full Text]  
  • Cha, R., Brown, W. J., Rybak, M. J. (2003). Bactericidal Activities of Daptomycin, Quinupristin-Dalfopristin, and Linezolid against Vancomycin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 47: 3960-3963 [Abstract] [Full Text]  
  • Jacqueline, C., Caillon, J., Le Mabecque, V., Miegeville, A.-F., Donnio, P.-Y., Bugnon, D., Potel, G. (2003). In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 51: 857-864 [Abstract] [Full Text]  
  • Bell, J. M., Turnidge, J. D., Ballow, C. H., Jones, R. N., the ZAPS Regional Participants, (2003). Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. J Antimicrob Chemother 51: 339-345 [Abstract] [Full Text]  
  • Grohs, P., Kitzis, M.-D., Gutmann, L. (2003). In Vitro Bactericidal Activities of Linezolid in Combination with Vancomycin, Gentamicin, Ciprofloxacin, Fusidic Acid, and Rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 418-420 [Abstract] [Full Text]  
  • Jacqueline, C., Batard, E., Perez, L., Boutoille, D., Hamel, A., Caillon, J., Kergueris, M.-F., Potel, G., Bugnon, D. (2002). In Vivo Efficacy of Continuous Infusion versus Intermittent Dosing of Linezolid Compared to Vancomycin in a Methicillin-Resistant Staphylococcus aureus Rabbit Endocarditis Model. Antimicrob. Agents Chemother. 46: 3706-3711 [Abstract] [Full Text]  
  • Allen, G. P., Cha, R., Rybak, M. J. (2002). In Vitro Activities of Quinupristin-Dalfopristin and Cefepime, Alone and in Combination with Various Antimicrobials, against Multidrug-Resistant Staphylococci and Enterococci in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 46: 2606-2612 [Abstract] [Full Text]  
  • Srinivasan, A., Dick, J. D., Perl, T. M. (2002). Vancomycin Resistance in Staphylococci. Clin. Microbiol. Rev. 15: 430-438 [Abstract] [Full Text]  
  • Drago, L., De Vecchi, E., Valli, M., Nicola, L., Gismondo, M. R. (2002). Effect of Linezolid in Comparison with That of Vancomycin on Glycocalix Production: In Vitro Study. Antimicrob. Agents Chemother. 46: 598-599 [Full Text]  
  • Gander, S., Hayward, K., Finch, R. (2002). An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. J Antimicrob Chemother 49: 301-308 [Abstract] [Full Text]  
  • Vera-Cabrera, L., Gomez-Flores, A., Escalante-Fuentes, W. G., Welsh, O. (2001). In Vitro Activity of PNU-100766 (Linezolid), a New Oxazolidinone Antimicrobial, against Nocardia brasiliensis. Antimicrob. Agents Chemother. 45: 3629-3630 [Abstract] [Full Text]  
  • Grif, K., Dierich, M. P., Pfaller, K., Miglioli, P. A., Allerberger, F. (2001). In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 48: 209-217 [Abstract] [Full Text]  
  • Dailey, C. F., Dileto-Fang, C. L., Buchanan, L. V., Oramas-Shirey, M. P., Batts, D. H., Ford, C. W., Gibson, J. K. (2001). Efficacy of Linezolid in Treatment of Experimental Endocarditis Caused by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 2304-2308 [Abstract] [Full Text]  
  • Munckhof, W. J., Giles, C., Turnidge, J. D. (2001). Post-antibiotic growth suppression of linezolid against Gram-positive bacteria. J Antimicrob Chemother 47: 879-883 [Abstract] [Full Text]  
  • Stevens, D. L., Smith, L. G., Bruss, J. B., McConnell-Martin, M. A., Duvall, S. E., Todd, W. M., Hafkin, B. (2000). Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections. Antimicrob. Agents Chemother. 44: 3408-3413 [Abstract] [Full Text]  
  • Wynalda, M. A., Hauer, M. J., Wienkers, L. C. (2000). Oxidation of the Novel Oxazolidinone Antibiotic Linezolid in Human Liver Microsomes. Drug Metab. Dispos. 28: 1014-1017 [Abstract] [Full Text]  
  • Noskin, G. A., Siddiqui, F., Stosor, V., Hacek, D., Peterson, L. R. (1999). In Vitro Activities of Linezolid against Important Gram-Positive Bacterial Pathogens Including Vancomycin-Resistant Enterococci. Antimicrob. Agents Chemother. 43: 2059-2062 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»